Brimonidine Tartrate Ophthalmic Solution NDC 70756-677

NDC codes

FDA NDC Directory

Product NDC (as listed)70756-677Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70756-0677Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70756-677-30	70756067730	1 BOTTLE, DROPPER in 1 CARTON (70756-677-30) / 5 mL in 1 BOTTLE, DROPPERMarketed from Jun 1, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Brimonidine Tartrate Ophthalmic Solution
Generic name (nonproprietary): brimonidine tartrate ophthalmic solution
Active ingredients: Brimonidine tartrate — 1 mg/mL
Dosage form: Solution/ drops
Route: Ophthalmic
Labeler: Lifestar Pharma LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220398
Marketing start: Jun 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 70756-677_94f317b9-76a6-4c32-99c2-c5310357bb97SPL ID 94f317b9-76a6-4c32-99c2-c5310357bb97SPL set ID f6666d85-f810-4869-993d-e8ae35b4517fRxCUI 861204UNII 4S9CL2DY2HUPC 0370756677307, 0370756679356, 0370756678304
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470756067730 followed by a unit qualifier and the quantity

Package 70756-0677-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 3, 2026.

Indications (excerpt from the label)

Brimonidine tartrate ophthalmic solution 0.1% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine tartrate ophthalmic solution is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 220398

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220398
Product	Strength	Form · route	Labeler	Product NDC
Brimonidine Tartrate Ophthalmic Solution	Brimonidine tartrate 1 mg/mL	Solution/ dropsOphthalmic	Lifestar Pharma LLC	70756-678
Brimonidine Tartrate Ophthalmic Solution	Brimonidine tartrate 1 mg/mL	Solution/ dropsOphthalmic	Lifestar Pharma LLC	70756-679